Tom H. Johnston - Concepedia

Author

Tom H. Johnston

Also Known As

T JOHNSTON, T Johnston, T M Johnston, T. H. Johnston, T. Johnston, T.H. Johnston, Tom H Johnston, Tom H. Johnston, Tom Johnston, Tom M. Johnston

Publications

3.1K

Citations

H-Index

Concepts

All Affiliations

Toronto Western Hospital University Health Network University of Toronto Atuka (Canada)The University of Western Australia

About

Tom H. Johnston is an author at Toronto Western Hospital specializing in medicine, neuroscience, and neuropharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	24	1.1K
2	Social Sciences	7	7	406
3	Health Sciences	2	2	56
4	Cell Biology	1	1	26
5	Immunology	1	1	23

Tom H. Johnston

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
Increased 5‐HT<sub>2A</sub> receptors in the temporal cortex of parkinsonian patients with visual hallucinations Philippe Huot, Tom H. Johnston, Tayyeba Darr, Movement Disorders NeuropsychologyWell-formed Visual HallucinationsPsychopharmacologyTemporal CortexSocial Sciences	2010	151
Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease James B. Koprich, Tom H. Johnston, M. Gabriela Reyes, Molecular Neurodegeneration	2010	144
Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease Tom H. Johnston, Susan H. Fox, Matthew J. McIldowie, Journal of Pharmacology and Experimental Therapeutics	2010	137
Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein James B. Koprich, Tom H. Johnston, Philippe Huot, PLoS ONE	2011	107
Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease Naomi P. Visanji, Jordi Gómez-Ramírez, Tom H. Johnston, Movement Disorders	2006	93
Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease Naomi P. Visanji, Susan H. Fox, Tom H. Johnston, Neurobiology of Disease Parkinson DiseaseAnimal ModelsNeuropharmacologyNeuroscienceNeurology	2008	92
Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers<i>In Vitro</i>and in the MPTP-Lesioned Primate:<i>R</i>-MDMA Reduces Severity of Dyskinesia, Whereas<i>S</i>-MDMA Extends Duration of ON-Time Philippe Huot, Tom H. Johnston, Katie D. Lewis, Journal of Neuroscience	2011	83
Subcellular redistribution of the synapse‐associated proteins PSD‐95 and SAP97 in animal models of Parkinson&s disease and L‐DOPA‐induced dyskinesia Joanne E. Nash, Tom H. Johnston, G.L. Collingridge, The FASEB Journal L-dopa AdministrationSynaptic TransmissionNeurotransmitterNeurotransmissionSubcellular Redistribution	2005	78
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP <sup>+</sup> in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease Naomi P. Visanji, Antonia Orsi, Tom H. Johnston, The FASEB Journal	2008	76
The selective mu‐opioid receptor antagonist adl5510 reduces levodopa‐induced dyskinesia without affecting antiparkinsonian action in mptp‐lesioned macaque model of Parkinson's disease James B. Koprich, Susan H. Fox, Tom H. Johnston, Movement Disorders	2011	68

Page 1